Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31 2021 - 08:00PM
Business Wire
Biocept (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays and services, today announced that it has granted
inducement stock options to purchase an aggregate of 220,800 shares
of its common stock to 16 new employees. These inducement stock
options have a grant date of August 31, 2021, and were granted as
inducements material to the new employees entering into employment
with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement stock options have an exercise price of $3.62 per
share, the closing price of Biocept’s common stock on August 31,
2021, are non-qualified stock options, have a ten-year term and
vest over four years, with 25% of the shares vesting on the
one-year anniversary of the vesting commencement date and the
remaining 75% of the shares vesting in equal monthly installments
over the following 36 months, subject to the new employee’s
continued service with Biocept through the applicable vesting
dates. The inducement stock options are subject to the terms and
conditions of Biocept’s Amended and Restated 2013 Equity Incentive
Plan.
About Biocept
Biocept, Inc., develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSide cerebrospinal fluid assay, designed to diagnose cancer that
has metastasized to the central nervous system. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210831006038/en/
Investors: Jody Cain, LHA Investor Relations Jcain@lhai.com,
310-691-7100
Media: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Mar 2023 to Mar 2024